Trial · NCT01075815
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Implantation Rate | Day 35-42 post ovum pick-up (OPU) (34-38 hours post recombinant human choriogonadotropin day {end of stimulation cycle}[approximately 28 days]) | Intention to treat (ITT) population included all randomized participants who had received at least 1 dose of the study medication. | sacs per embryo | MEAN |
| SECONDARY | Mean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day | r-hCG day (end of stimulation cycle [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | follicles | MEAN |
| SECONDARY | Mean Number of Oocytes Retrieved | 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | oocytes | MEAN |
| SECONDARY | Number of Mature Oocytes Retrieved | 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | mature oocytes | NUMBER |
| SECONDARY | Number of Fertilized Oocytes (2 Pronuclei [PN]) | 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | 2PN oocytes | NUMBER |
| SECONDARY | Number and Quality of Embryos | Day 2-3 post OPU (34-38 hours post r-hCG day {end of stimulation cycle}[approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. Here N represents the number of participants who had at least one fertilized oocyte. | embyros | NUMBER |
| SECONDARY | Number of Participants With Biochemical Pregnancies | 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | participants | NUMBER |
| SECONDARY | Number of Participants With Clinical Pregnancies | 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | participants | NUMBER |
| SECONDARY | Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH) | 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | IU | MEAN |
| SECONDARY | Estradiol (E2) Levels on r-hCG Day | r-hCG day (end of stimulation cycle [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. Here N represents the number of participants with plasma E2 levels at r-hCG day. | picogram/milliter (pg/mL) | MEAN |
| SECONDARY | Number of Ovarian Stimulation Days | S1 up to r-hCG day (end of stimulation cycle [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | Days | MEAN |
| SECONDARY | Number of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response | Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. | cycles | NUMBER |
| SECONDARY | Total Number of Births | Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | ITT population included all randomized participants who had received at least 1 dose of the study medication. Here N represents number of participants evaluated for this measure. | births | NUMBER |
| SECONDARY | Number of Participants With Adverse Events (AEs) | Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | Safety population included all participants who had received at least 1 dose of the study medication. | participants | NUMBER |
| SECONDARY | Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS) | Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | Safety population included all participants who had received at least 1 dose of the study medication. | participants | NUMBER |
| SECONDARY | Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS) | Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days]) | Safety population included all participants who had received at least 1 dose of the study medication. | cycles | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01075815/outcomes